Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 30, 2011; DOI: 10.1158/1078-0432.CCR-11-0476 3
2

Translational Relevance
The favorable clinical outcome of bortezomib therapy in multiple myeloma (MM) patients provided impetus for the development of second generation small molecule proteasome inhibitors with the goals of improving efficacy of proteasome inhibition, enhancing anti-tumor activity, and reducing toxicity, as well as providing flexible dosing schedules and patient convenience. In the present study, we utilized both in vitro and in vivo MM xenograft models to show antitumor efficacy of a novel orally bioactive proteasome inhibitor MLN9708. Moreover, combination regimens of MLN9708 with bortezomib, lenalidomide, or dexamethasone induce synergistic anti-MM activity. Our preclinical data showing efficacy of MLN9708 in MM disease models provide the framework for clinical evaluation of MLN9708, either alone or in combination, to improve outcome in MM. 
Introduction
Normal cellular processes such as DNA replication, cell cycle, cell growth and survival, inflammation, transcription, and apoptosis are modulated by the ubiquitinproteasome signaling pathway (UPS) (1) (2) (3) , which facilitates proteolysis of key regulatory proteins. Importantly, deregulation in UPS is linked to the pathogenesis of various human diseases (3) , and targeting components of UPS therefore offers great promise in novel therapeutic strategies. Bortezomib (VELCADE TM ) is the first-in-class proteasome inhibitor, approved by FDA for the treatment of multiple myeloma (MM) and relapsed mantle cell lymphoma (3) (4) (5) (6) (7) . Although very effective, dose-limiting toxicities and the development of resistance limit its long-term utility (8, 9) , there is therefore a need for development of novel proteasome inhibitors with equipotent efficacy and improved safety profile.
Recent preclinical pharmacology studies demonstrated that a second-generation small molecule proteasome inhibitor MLN9708 (Millennium Pharmaceuticals, Inc.) has a shorter proteasome dissociation half-life than bortezomib, as well as improved pharmacokinetics, pharmacodynamics, and antitumor activity in xenograft models (10) .
In contrast to bortezomib, MLN9708 is an orally bioavailable proteasome inhibitor and shows efficacy at various dosing routes and regimens. Upon exposure to aqueous solutions or plasma, MLN9708 rapidly hydrolyzes to its biologically active form MLN2238. Similar to bortezomib, MLN2238 is a boronic acid analog which was identified by screening a large pool of boron-containing proteasome inhibitors with physiochemical properties distinct from bortezomib (10, 11) . In the present study, we examined the anti-tumor activity of MLN2238 using both in vitro and in vivo MM models.
Research. 
Material and Methods
Cell culture MM.1S {Dexamethasone-(Dex) sensitive}, MM.1R (Dex-resistant), RPMI-8226, OPM1, OPM2, H929 and INA-6 (IL-6-dependent) human MM cell lines were cultured in complete medium (RPMI-1640 media supplemented with 10% FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine). ANBL-6-bortezomib-sensitive (ANBL-6.WT) and bortezomib-resistant (ANBL-6.BR) were kindly provided by Dr. Robert Orlowski (M.D. Anderson Cancer Center, TX). Tumor cells from MM patients were purified (greater than 95% purity) by CD138 positive selection using the Auto MACS magnetic cell sorter (Miltenyi Biotec Inc., Auburn, CA). Informed consent was obtained from all patients in accordance with the Helsinki protocol.
PBMCs from normal healthy donors were maintained in culture medium, as above. In vitro proteasome activity assays Proteasome activity assay was performed using 20S Proteasome Assay Kit, ADS-Activated (Calbiochem) as previously described (12, 13) , with some modifications. Briefly, MM.1S cells were lysed in RIPA buffer and 20μg (10μl) of protein was used in a total volume of 200μl reaction buffer (20mmol/L Hepes, pH7.6, 0.5mmol/L EDTA) with 0.03% SDS except for trypsin-like activity assay.
The substrates utilized for measuring CT-L, T-L or C-L proteasome activity were SucLeu-Leu-Val-Try-AMC (10μM), Bz-Val-Gly-Arg-AMC (50μM), and Z-Leu-Leu-Glu-AMC (10μM) respectively. The reaction was initiated by adding 10μl of each substrate, and free AMC fluorescence was quantified using 380/460 nm filter set in a SpestraMax M2e fluorometer (Bucher biotec AG, Basel Switzerland).
Cell viability, proliferation, and apoptosis assays Cell viability was assessed by 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Chemicon International Inc., Temecula, CA) (14) and CellTiter-Glo (Progema, Madison, WI) assays, according to the manufacturer 's instructions. Cell proliferation analysis in coculture experiments with patient-derived BMSCs was performed using thymidine incorporation, as described previously (14) . Apoptosis was quantified using Annexin V/PI staining kit, as per manufacturer's instructions (R&D Systems, Inc. Minneapolis, MN), and analysis on a FACSCalibur (Becton Dickinson, San Jose, CA).
Immunoblotting Western blot analysis was performed as previously described (15) using antibodies against PARP (BD Bioscience Pharmingen, San Diego, CA), Caspase-3, Caspase-8, Caspase-9, p21, E2F, Cyclin D1, Cdk6, p-Rb (Cell Signaling, Beverly, MA), p53, NOXA, PUMA, Bip, CHOP, eIF2-α, or β-actin (Santa Cruz, CA). Use Committee at the Dana-Farber Cancer Institute. MLN2238 was dissolved in 5% 2-hydroxypropyl-β-cyclodextrin at 2 mg/ml concentration. The human plasmacytoma xenograft tumor model was performed as previously described (13, 15, 16 In situ detection of apoptosis, and assessment of angiogenesis Mice tumor sections were subjected to IHC staining for TUNEL, and for caspase-3 activation (13).
Ki-67 was assessed by IHC staining to quantify proliferation. Tumor angiogenesis was assessed by IHC staining for VEGFR2, and Pecam-αsma expression (13) .
Immunostained tissues were imaged using confocal microscopy (FV1000, Olympus, Center Valley, PA). A recent study showed that peripheral neuropathy associated with bortezomib therapy may be, in part, due to blockade of neuronal cell survival protease HtrA2/Omi (18) . In the present study, treatment of MM cells with bortezomib inhibited HtrA2/Omi; and importantly, no significant inhibition of HtrA2/omi was noted in response to MLM2238 treatment (Fig 1F; P < 0.004). These data highlight another distinction between bortezomib and MLN2238; however, the effect of MLN2238 on other proteases remains to be examined. Nonetheless, our findings suggest that MLN2238 targets proteasomes; and importantly, retains the potency and selectivity of bortezomib against CT-L proteasome activity. refractory patients showed increased in vitro cytotoxicity in response to MLN2238 vs. bortezomib (data not shown). These findings show the ability of MLN2238 to trigger cytotoxicity even in tumor cells obtained from patient resistant to bortezomib, Dex, or lenalidomide therapies. In order to further determine whether MLN2238 overcomes bortezomib-resistance, we utilized previously characterized (25) bortezomib-sensitive (ANBL-6.WT) and bortezomib-resistant (ANBL-6.BR) MM cell lines. As seen in Figure   2D , the IC 50 ratio (ANBL-6.BR/ANBL-6.WT) of MLN2238 is significantly less than bortezomib (P < 0.01; n= 3), demonstrating the ability of MLN2238 to overcome bortezomib-resistance. In the context of mechanism(s) mediating bortezomibresistance, a recent study has linked it to increased signaling through the insulin-like growth factor-1/Akt axis (25) ; however, involvement of other signaling cascades cannot be excluded. Furthermore, a differential proteasome content/activity profile, abnormal or mutated proteasome subunits, and/or ER stress levels may contribute to bortezomib resistance. These issues remain to be examined in a broader panel of MM cell lines and patient cells. Finally, in the present study, MLN2238 at the IC 50 for MM cells does not significantly affect the viability of normal PBMCs (Fig 2F) , suggesting specific anti-MM activity and a favorable therapeutic index for MLN2238.
Statistical Analysis
MLN2238 inhibits human MM cell growth in vivo and prolongs survival in xenograft mouse model Having shown that MLN2238 induces apoptosis in MM cells
in vitro, we examined the in vivo efficacy of MLN2238 given intravenously or orally using a human plasmacytoma MM.1S xenograft mouse model (13, 16) . Treatment of tumorbearing mice with intravenous injection of MLN2238 significantly (P = 0.001) inhibited MM tumor growth and prolonged survival (87%; P < 0.001) of these mice (Fig 3A and Research. 
3B, respectively). Bortezomib treatment also reduced tumor progression (Fig 3A) , albeit to a lesser extent than MLN2238. Moreover, we found that MLN2238-treated mice survived for a longer time than mice receiving bortezomib (P < 0.01; CI =95%). In addition, blood chemistry profiles of MLN2238-treated mice showed normal levels of creatinine, hemoglobin, and bilirubin (Fig 3C) . Examination of the xenografted tumor sections showed that MLN2238, but not vehicle alone, dramatically increased the number of cleaved-caspase-3 positive (Red color) cells (Fig 3D) . Similarly, MLN2238
increased the number of TUNEL-positive (Green color) cells compared to vehicle treatment ( Fig 3D) . In agreement with these data, a significant decrease in proliferation marker Ki-67 (Red color) was noted in tumor sections from MLN2238-treated mice relative to tumors from control mice (Fig 3D) . Finally, treatment of tumor-bearing mice with oral doses of MLN2238 significantly (P = 0.001) inhibited MM tumor growth and prolonged survival (P < 0.01) of these mice (Fig 3E and 3F, respectively) . These in vivo data confirm our in vitro findings showing potent apoptotic activity of MLN2238 against MM cells.
Prior studies have established that MM cell growth is associated with angiogenesis, which predominantly occur via vascular endothelial growth factor (VEGF) pathway (26, 27) . To determine whether MLN223 triggers anti-angiogenic activity, we directly evaluated tumors harvested from mice by immunostaining using two distinct markers of angiogenesis, VEGFR2 and Pecam. As seen in Fig 3D, MLN2238 decreased the numbers of VEGFR2-and Pecam-positive cells. These data suggest that besides inducing apoptosis, MLN2238 also inhibit tumor-associated angiogenic activity.
Taken together, our findings demonstrate that MLN2238 reduces tumor growth, prolongs survival, and is well tolerated in vivo.
Mechanisms mediating anti-MM activity of MLN2238 Studies to date provide evidence for activation of pleiotropic cell death signaling cascades in response to proteasome inhibition (28, 29) . This is likely due to the fact that the majority of cellular proteins undergo degradation through proteasome; and, blockade of proteasome negatively affects this normal cellular process resulting in accumulation of unwanted proteins, and subsequent activation of multiple cell death signaling. In the light of this notion, we examined the effect of MLN2238 on some of the major apoptotic signaling pathways triggered by similar class of agents in MM cells.
Effect of MLN2238 on caspases Treatment of H929 and MM.1S MM cells with
MLN2238 triggered a marked increase in proteolytic cleavage of poly(ADP) ribose polymerase (PARP), a signature event during apoptosis (Fig 4A and 4B) . Furthermore, MLN2238 induced cleavage of caspase-3, an upstream activator of PARP (Fig 4A and   4B ). Mitochondria mediate apoptotic signaling via activation of cell death initiator caspase, pro-caspase 9 (30). Similarly, Fas associated death-domain (FADD) protein is an essential component of the death-inducing signaling complexes (DISCs), resulting in autoactivation of pro-caspase-8. Our data show that MLN2238 induces activation of both caspase-9 (intrinsic) and casapse-8 (extrinsic) apoptotic pathways in H929 and MM.1S and cells (Fig 4A and 4B, respectively) . Studies using biochemical inhibitors showed that inhibition of either caspase-8 (IETD-FMK) or caspase-9 (LEHD-FMK) resulted in marked abrogation of MLN2238-triggered cytotoxicity (Fig 4C) . Additionally, attenuation of MLN2238-triggered cell death. These findings suggest that 1) MLN2238 triggers both mitochondria-dependent and -independent signaling pathways; and 2) MLN2238-induced apoptosis occurs in a caspase-dependent manner.
pan-caspase inhibitor (Z-VAD-FMK) also attenuated MLN2238-induced cytotoxicity (Fig
Effect of MLN2238 on p53 pathway
The molecular pathways leading to caspase induction includes activation of tumor suppressor p53, which coordinates cellular response to stress signaling pathways via cell cycle arrest, and apoptosis (31, 32).
Examination of MLN2238-treated MM cells showed an increase in both p53 and p21 (Fig 4D) . The induction of p21 may account for MLN2238-induced growth arrest (data not shown). Prior studies have also linked p53 pathway to activation of mitochondrial apoptotic signaling via BH3-only proteins Noxa and Puma (33, 34) ; and, we found that MLN2238 triggered robust induction of Noxa and Puma (Fig 4D) . This finding is consistent with the observed MLN2238-induced caspase-9 induction that occurs via mitochondria (Fig 4A and 4B) . Furthermore, the p53-signaling cascade is known to communicate with retinoblastoma (Rb)-E2F axis (35) . Treatment of MM.1S and MM.1R cells with MLN2238 downregulated pRb with an expected upregulation of its downstream target protein E2F (Fig 4E and 4F) . Similarly, cyclin D1 and its target protein Cdk6 were markedly decreased upon treatment with MLN2238 (Fig 4E and 4F) .
Effect of MLN2238 on endoplasmic reticulum (ER) stress pathway Proteasome
inhibition is associated with induction of ER stress pathway and the unfolded protein response (13, 36, 37) . Analysis of proteins mediating ER stress pathway showed that MLN2238 induces eIf2-α kinase activity and protein levels of Bip and CHOP/GADD153 (Fig 4G) . Of note, ER stress signaling is also linked to activation of p53-Noxa-Puma signaling axis (38) , suggesting a potential crosstalk between these pathways during MLN2238-induced apoptosis in MM cells. It is conceivable that MLN2238, like bortezomib, trigger pleiotropic signaling pathways; however, due to the shorter dissociation (t ½ ) characteristics of MLN2238 compared to bortezomib, the kinetics of alterations in stress response signaling may vary and this issue remains to be defined.
Nonetheless, our mechanistic data shows that MLN2238-induced apoptosis in MM cells is caspase-dependent and correlates with activation of p52-p21, p53-Noxa-Puma, Rb-E2F, and ER stress signaling pathways. and form capillary-like tube structures similar to in vivo neovascularization, a process dependent on cell-matrix interaction, cellular communication, and cellular motility. This assay therefore provides evidence for anti-angiogenic effects of drugs/agents. HUVECs were pretreated with vehicle (DMSO) or MLN2238 (10 nM) for 8h; washed in media and seeded in 96-well culture plates coated with Matrigel; and then incubated for additional 4h, followed by analysis of tube formation using an inverted microscope. As seen in Fig   5B, tubule formation was significantly decreased in the MLN2238-treated cells, but not after treatment with DMSO alone (P < 0.001, n=3). HUVEC cell viability was assessed using trypan blue exclusion assay: < 5% cell death was observed after MLN2238 treatment, excluding the possibility that drug-induced inhibition of capillary-tube formation was due to cell death. These in vitro data corroborate with our in vivo findings in animal model (Fig 3C) to show anti-angiogenic activity of MLN2238.
MLN2238 targets nuclear factor-kappa B (NF-κB) NF-κB plays a key role
during MM cell adhesion-induced cytokine secretion in BMSCs, which in turn triggers MM cell growth in a paracrine manner (15, 39, 42) . Reports have also linked constitutive activation of non-canonical NF-κB pathway to the genetic abnormalities/mutations (43, 44) , allowing for an autocrine growth of MM cells. Importantly, constitutive NF-κB activity in primary tumor cells from MM patients renders these cells refractory to inhibition by bortezomib (45) , and in fact, bortezomib induces canonical NF-κB activity (46) . Given the findings from these studies, we examined whether MLN2238 affects NF-κB. ML2238, in a time-dependent manner, inhibits both constitutive and TNF-α-induced NF-κB activation in MM cells (Fig 5C-5F ; P < 0.05; n =3). These data suggest that MLN2238 is a potent inhibitor of both canonical and non-canonical NF-κB pathways. 
Combined treatment with MLN2238 and lenalidomide, Dexamethasone or HDAC inhibitor SAHA induces synergistic anti-MM activity Preclinical studies (47) (48) (49) provided the basis for clinical trials of proteasome inhibitor bortezomib in combination with lenalidomide, Dex and HDAC inhibitors (50) . Given that MLN2238, like bortezomib, is a boronic acid analog, we examined whether ML2238 similarly enhances the anti-MM activity of other agents. MM.1S cells were first treated with both MLN2238 and lenalidomide simultaneously across a range of concentrations for 48h, and then analyzed for viability using MTT assay. An analysis of synergistic anti-MM activity using the Chou and Talalay method (17) demonstrated that the combination of low concentrations of MLN2238 and lenalidomide triggered synergistic anti-MM activity, with a combination index (CI) < 1.0 (Fig 6A) .
In addition to proteasomal degradation, intracellular protein catabolism also occurs via an HDAC-dependent aggressome-autophagic signaling pathway (51-53).
Our prior study showed that inhibition of both mechanisms of protein catabolism by combining bortezomib and HDAC inhibitor induced significant cytotoxicity in MM cells (51) . Recent clinical trials combining bortezomib and HDAC inhibitor vorinostat showed promising outcome in relapsed and refractory MM, including activity among some patients with prior exposure to bortezomib (54) . In the light of these studies, we examined whether the combination of MLN2238 with HDAC inhibitor SAHA triggers synergistic anti-MM activity. MM.1S cells were treated with both MLN2238 and SAHA simultaneously across a range of concentrations for 48h, and then analyzed for viability. -11-0476 ( Fig 6B) . These data confirm the potential for clinical trials combining MLN2238 and
HDAC inhibitors
We next examined whether MLN2238 adds to the anti-MM activity of conventional anti-MM agent Dex. As with lenalidomide and SAHA, the combination of MLN2238 with Dex triggered synergistic anti-MM activity, evidenced by a significant decrease in viability of MM.1S cells (Fig 6C) . Although definitive evidence of decreased toxicity of combination therapy awaits results of clinical trials, the synergy observed in vitro may allow for use of lower doses and decreased toxicity. during the last 20 mins before cells were harvested. Cells were then subjected to p65 and p52 NF-κB activity analysis using ELISA. Data presented are the means plus or minus SD (n = 3; P < 0.004). Error bars represent standard deviation. 
